Ieq Capital LLC Has $176,000 Position in Sana Biotechnology, Inc. $SANA

Ieq Capital LLC lifted its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 428.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 104,832 shares of the company's stock after buying an additional 85,004 shares during the period. Ieq Capital LLC's holdings in Sana Biotechnology were worth $176,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in SANA. Millennium Management LLC boosted its position in shares of Sana Biotechnology by 604.8% during the fourth quarter. Millennium Management LLC now owns 728,901 shares of the company's stock worth $1,188,000 after buying an additional 625,481 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Sana Biotechnology by 44.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company's stock worth $2,538,000 after buying an additional 478,596 shares during the period. Nuveen LLC acquired a new position in shares of Sana Biotechnology during the first quarter worth approximately $589,000. Two Sigma Investments LP boosted its position in shares of Sana Biotechnology by 228.4% during the fourth quarter. Two Sigma Investments LP now owns 480,298 shares of the company's stock worth $783,000 after buying an additional 334,042 shares during the period. Finally, Deutsche Bank AG boosted its position in shares of Sana Biotechnology by 87.9% during the first quarter. Deutsche Bank AG now owns 666,392 shares of the company's stock worth $1,120,000 after buying an additional 311,692 shares during the period. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Morgan Stanley initiated coverage on Sana Biotechnology in a research report on Thursday, July 3rd. They set an "overweight" rating and a $12.00 price objective for the company. JMP Securities restated a "market outperform" rating and issued a $5.00 target price on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Sana Biotechnology presently has a consensus rating of "Buy" and a consensus price target of $8.00.

Sana Biotechnology Stock Performance

Shares of NASDAQ SANA traded down $0.18 during trading on Friday, hitting $3.22. The company had a trading volume of 3,000,261 shares, compared to its average volume of 4,056,273. The company has a market cap of $765.75 million, a P/E ratio of -3.04 and a beta of 1.88. Sana Biotechnology, Inc. has a 52 week low of $1.26 and a 52 week high of $7.30. The business's 50-day moving average is $3.72 and its 200 day moving average is $2.71.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. On average, research analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.